New stock news | DiZhe Medicine (688192.SH) Hong Kong IPO prospectus is invalid.

Dezhe (Jiangsu) Pharmaceutical Co., Ltd. (referred to as Dezhe Pharmaceutical (688192.SH)) submitted its Hong Kong IPO prospectus on January 23, 2026, which expired after 6 months on July 23, 2026, with Goldman Sachs and Huatai International as its joint sponsors. According to the prospectus, Dezhe Pharmaceutical is a commercial-stage biopharmaceutical company with a focus on the treatment of oncology and hematologic diseases. Their listed product, Shuwozhe, is the only globally approved small molecule epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of EGFR exon 20 insertion mutation-positive lung cancer. For the fiscal years of 2023, 2024, and the nine months ending September 30, 2025, the company achieved revenues of 91.289 million yuan, 360 million yuan, and 586 million yuan respectively.